Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 15, Issue 11, Pages 1647-1651Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2015.1092518
Keywords
Animal models; Middle East respiratory syndrome; Middle East respiratory syndrome coronavirus; receptor-binding domain; spike protein; vaccines
Ask authors/readers for more resources
The outbreaks of Middle East respiratory syndrome (MERS) previously in Middle East and recently in South Korea have raised serious concerns worldwide, reinforcing the importance of developing effective and safe vaccines against MERS-coronavirus (MERS-CoV). A number of vaccine candidates have been developed on the basis of viral vectors, recombinant proteins, DNAs, nanoparticles, and recombinant MERS-CoV, and some of them have shown efficacy in laboratory animals. However, the paucity of financial support has made it difficult to transfer effective candidates from the preclinical stage to clinical trials. Here, we summarize currently available MERS vaccine candidates and illustrate strategies for future development, with the aim of provoking government agencies and Big Pharma to invest more funds for developing efficacious and safe MERS vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available